Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals Inc (NASDAQ: IONS), Flexion Therapeutics (NASDAQ: FLXN) and Nevro (NYSE: NVRO)

By Austin Angelo

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ionis Pharmaceuticals Inc (NASDAQ: IONS), Flexion Therapeutics (NASDAQ: FLXN) and Nevro (NYSE: NVRO) with bullish sentiments.

Ionis Pharmaceuticals Inc (NASDAQ: IONS)

In a report released yesterday, Do Kim from BMO Capital reiterated a Buy rating on Ionis Pharmaceuticals Inc (NASDAQ: IONS), with a price target of $48. The company’s shares closed yesterday at $32.12.

According to TipRanks.com, Kim is a 4-star analyst with an average return of 9.2% and a 36.0% success rate. Kim covers the Healthcare sector, focusing on stocks such as Cynapsus Therapeutics, Tetralogic Pharma, and Fate Therapeutics.

Currently, the analyst consensus on Ionis Pharmaceuticals Inc is Moderate Buy and the average price target is $42, representing a 30.8% upside.

In a report issued on November 1, Piper Jaffray also reiterated a Buy rating on the stock.
Flexion Therapeutics (NASDAQ: FLXN)

BMO Capital analyst Gary Nachman reiterated a Buy rating on Flexion Therapeutics (NASDAQ: FLXN) yesterday. The company’s shares closed yesterday at $18.24.

According to TipRanks.com, Nachman is a 4-star analyst with an average return of 3.7% and a 51.2% success rate. Nachman covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Sucampo Pharmaceuticals, and Pacira Pharmaceuticals.

Currently, the analyst consensus on Flexion Therapeutics is Strong Buy and the average price target is $30, representing a 64.5% upside.

In a report issued on November 1, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $40 price target.
Nevro (NYSE: NVRO)

In a report released yesterday, Joanne Wuensch from BMO Capital reiterated a Buy rating on Nevro (NYSE: NVRO). The company’s shares closed yesterday at $89.12.

According to TipRanks.com, Wuensch is a 4-star analyst with an average return of 3.8% and a 59.0% success rate. Wuensch covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp., Zimmer Biomet Holdings, and Baxter International.

Currently, the analyst consensus on Nevro is Strong Buy and the average price target is $107.33, representing a 20.4% upside.

In a report issued on October 24, J.P. Morgan also maintained a Buy rating on the stock with a $112 price target.